| Organigram logo | |
| Nasdaq: OGI TSX: OGI | |
| Industry | Cannabis |
| Headquarters | 1400-145 King Street West, , |
| Revenue | US$247,177,000 (2024) |
Number of employees | 875 (2024) |
| Website | organigram |
| Footnotes /references [1] | |
Organigram Global Inc. is a cannabis company. [2] [3] The business has a facility in Moncton. [4]
Organigram is a Canadian company that produces and sells cannabis and cannabis-derived products, including dried flower, pre-rolls, vapes, concentrates, oils, and edibles, for both the adult-use and medical markets. [5] [6]
The company generates revenue through sales to provincial cannabis boards, direct sales to medical patients, and exports and partnerships in certain international markets. [6]
On March 24th, 2025, Organigram investors approved rebranding from Organigram Holdings to Organigram Global. [7] [8]
In 2023, the company reported a quarterly profit of $5.3 million, reversing a $1.3 million loss a year earlier, as revenue rose to $43.3 million from $30.4 million and margins improved. [4]
In November 2025, the company announced that James Yamanaka, a former executive at British American Tobacco, was being appointed CEO effective around January 15, 2026, and that he would also join the company’s board. [9]